PacificPharma Corp.
Excipients & Specialty Ingredients
Analytical & Bioanalytical Services
Company Overview
About
PacificPharma Corp. is a leading contract development and manufacturing organization headquartered in Finland. We specialize in Cell & Gene Therapy, Fill/Finish, Contract Research Organization (CRO) with state-of-the-art facilities serving clients globally.
Key Expertise
Packaging & Labeling, Aseptic Processing, Formulation Development, Analytical Services, Biologics Drug Product
Therapeutic Areas
Oncology
Hematology
Quick Facts
HQ:Finland
Founded:2001
Employees:13,342
Capabilities & Services
Core Capabilities
- Oral Solid Dose
- Solid Dose Manufacturing
- Formulation Development
Technology Platforms
Small Molecule API Manufacturer
Biologics Manufacturer
Cell & Gene Therapy
Fill/Finish
Dosage Forms
Lyophilized (Freeze-Dried)
Sterile Injectable
Containment Capabilities
BSL-2 (Biosafety Level 2)
Production Scales
R&D / Pre-clinical
Lab Scale
Pilot Scale
Batch Sizes
5000L+
1L-10L
1000L-5000L
10L-100L
Markets Served
Europe
Manufacturing Facilities
4 sites worldwide
PacificPharma Corp. - Headquarters
674 Industrial Boulevard, Turku, Turku, 36515
297,965 sq ft
Established 2001
Site Capabilities
Small Molecule API
Analytical Services
Method Development & Validation
Fill/Finish (Syringes)
Aseptic Processing
Regulatory Support
PacificPharma Corp. - North Carolina Facility
327 Pharma Drive, North Carolina, North Carolina, 90821
348,437 sq ft
Established 2017
Site Capabilities
Aseptic Processing
Fill/Finish (Vials)
Oral Solid Dose
Analytical Services
Fill/Finish (Syringes)
Liquid/Semi-Solid
PacificPharma Corp. - Oslo Facility
316 Technology Park, Oslo, Oslo, 72974
175,356 sq ft
Established 1997
Site Capabilities
Biologics Drug Substance
Oral Solid Dose
Method Development & Validation
Antibody-Drug Conjugates (ADC)
Sterile Injectable
Fill/Finish (Vials)
Small Molecule Drug Product
PacificPharma Corp. - Turku Facility
174 Science Way, Turku, Turku, 49841
469,953 sq ft
Established 2007
Site Capabilities
Biologics Drug Product
Biologics Drug Substance
Regulatory Support
Stability Studies
Analytical Services
Regulatory Approvals
Drug Approval TLGZS8
Health Canada · #APR-I2GFXCLW · 2018-04-01
Product Portfolio
Standard Formulation Service
BrochureOur comprehensive service offering for Dermatology and CNS (Central Nervous System) applications.
Tablet
Capsule
Suspension
Delivery: Intramuscular, Subcutaneous
Premium Fill-Finish Service
BrochureOur comprehensive service offering for Oncology and Dermatology applications.
Injectable
Capsule
Delivery: IV Infusion, Oral, Topical
Case Studies
3 published case studies showcasing past projects, challenges and outcomes.
Dermatology Small Molecule Development Partnership
Phase II
mRNA
May 2020 – Feb 2023
336 views
Successful Phase II manufacturing program for a top-10 pharma client.
Challenge
The client required rapid scale-up of their Dermatology therapeutic with aggressive timelines and complex analytical requirements.
Solution
We deployed our experienced team and state-of-the-art facilities to develop a robust manufacturing process. Key innovations included process intensification and real-time analytics.
Outcome
The program achieved all milestones on schedule. The product received regulatory approval and is now in commercial production.
Dermatology
Dermatology Monoclonal Antibody Development Partnership
Phase I
Gene Therapy
Cell Therapy
Oct 2021 – Apr 2023
261 views
Successful Phase I manufacturing program for a virtual pharma client.
Challenge
The client required rapid scale-up of their Dermatology therapeutic with aggressive timelines and complex analytical requirements.
Solution
We deployed our experienced team and state-of-the-art facilities to develop a robust manufacturing process. Key innovations included process intensification and real-time analytics.
Outcome
The program achieved all milestones on schedule. The product received regulatory approval and is now in commercial production.
Dermatology
Oncology
Rare Disease Small Molecule Development Partnership
Commercial
mRNA
Mar 2019 – Aug 2024
338 views
Successful Commercial manufacturing program for a emerging biotech client.
Challenge
The client required rapid scale-up of their Rare Disease therapeutic with aggressive timelines and complex analytical requirements.
Solution
We deployed our experienced team and state-of-the-art facilities to develop a robust manufacturing process. Key innovations included process intensification and real-time analytics.
Outcome
The program achieved all milestones on schedule. The product received regulatory approval and is now in commercial production.
Rare Disease
Respiratory
Customer Reviews
4.3
Overall Rating(Based on 18 reviews)
Project Management3.9
Technology Transfer4.5
On-Time Delivery3.9
Communication Responsiveness5.0
Innovation4.0
Company Documents
No documents available.
Loading CDMO intelligence...